Initiating PCSK9 Inhibition in Hospital for ACS: We Can, But Does That Mean We Should?

J Am Coll Cardiol. 2019 Nov 19;74(20):2463-2465. doi: 10.1016/j.jacc.2019.09.039.

Authors

Gregory G Schwartz¹, Bernard R Chaitman²

Affiliations

¹ Rocky Mountain Regional VA Medical Center and University of Colorado School of Medicine, Aurora, Colorado. Electronic address: Gregory.Schwartz@va.gov.
² Center for Comprehensive Cardiovascular Care, St. Louis University School of Medicine, St. Louis, Missouri.

PMID: 31727283
DOI: 10.1016/j.jacc.2019.09.039

No abstract available

Keywords: LDL-C; PCSK9 inhibitor; acute coronary syndrome; ezetimibe; statin.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Acute Coronary Syndrome*
Antibodies, Monoclonal, Humanized
Cholesterol, LDL
Ezetimibe
Humans
Proprotein Convertase 9*

Substances

Antibodies, Monoclonal, Humanized
Cholesterol, LDL
PCSK9 protein, human
Proprotein Convertase 9
Ezetimibe
evolocumab